Citations

Clear

96 citation(s) found for "Serrano, Geidy".

Heart rate variability as a screening tool for Parkinson’s disease has age-dependent performance (P1.110)
Mehta, Shyamal, Hentz, Joseph G. , Beach, Thomas G. , Shill, Holly A. , Driver‐Dunckley, Erika , Langston, J. William, Adler, Charles, Christiansen, Michael , Mehta, Shyamal H. , Serrano, Geidy E. , Sabbagh, Marwan Noel , Davis, Kathryn A.

Mayo Clinic

Neurology | December 7, 2023 | Volume: 88 | Issue: 16_supplement | Pages: No page available

10.1212/wnl.88.16_supplement.p1.110 Get It

Sirtuin 3 is down-regulated in Apolipoprotein E4 carriers with Alzheimer’s disease (P5.011)
Yin, Junxiang , Han, Peng Cheng, Caselli, Richard J. , Beach, Thomas G., Reiman, Eric M. , Shi, Jiong , Han, Pengcheng, Serrano, Geidy E.

Mayo Clinic

Neurology | December 6, 2023 | Volume: 84 | Issue: 14_supplement | Pages: No page available

10.1212/wnl.84.14_supplement.p5.011 Get It

PACAP deficit and Cognitive Function in Mild Cognitive Impairment and Alzheimer Dementia (P4.084)
Han, Pengcheng, Caselli, Richard J. , Beach, Thomas G. , Reiman, Eric M. , Shi, Jiong , Baxter, Leslie C. , Serrano, Geidy E.

Mayo Clinic

Neurology | December 6, 2023 | Volume: 84 | Issue: 14_supplement | Pages: No page available

10.1212/wnl.84.14_supplement.p4.084 Get It

Olfactory dysfunction in incidental Lewy body disease and Parkinson's disease: An update (P4-11.005)
Hasan, Shemonti , Sue, Lucia I., Shill, Holly A. , Mehta, Shyamal H. , Beach, Thomas G. , Driver‐Dunckley, Erika , Adler, Charles H. , Zhang, Nan , Serrano, Geidy E.

Mayo Clinic

Neurology | December 6, 2023 | Volume: 98 | Issue: 18_supplement | Pages: No page available

10.1212/wnl.98.18_supplement.3775 Get It

Accuracy of the Early Diagnosis of Parkinson's Disease
Beach, Thomas G. , Adler, Charles H. , Shill, Holly A. , Driver‐Dunckley, Erika , Mehta, Shyamal H. , Adler, C H , Zhang, Nan , Serrano, Geidy E.

Mayo Clinic

Movement Disorders | August 11, 2023 | Volume: 38 | Issue: 8 | Pages: 1573-1574

10.1002/mds.29556 | PMID 37565398 Get It

Longitudinal motor decline in dementia with Lewy bodies, Parkinson disease dementia, and Alzheimer's dementia in a community autopsy cohort
Choudhury, Parichita , Belden, Christine M. , Driver‐Dunckley, Erika, Mehta, Shyamal H. , Shill, Holly A. , Beach, Thomas G. , Driver-Dunckley, Erika, Choudhury, Parichita , Zhang, Nan , Adler, Charles H. , Chen, Kewei , Driver‐Dunckley, Erika , Shprecher, David , Serrano, Geidy E. , Atri, Alireza

Mayo Clinic

Alzheimer's & Dementia | July 8, 2023 | Volume: 19 | Issue: 10 | Pages: 4377-4387

10.1002/alz.13357 | PMID 37422286 Get It

Abstract INTRODUCTION We examined the progression of extrapyramidal symptoms and signs in autopsy‐confirmed dementia with Lewy bodies (DLB), Parkinson's disease dementia (PDD), and Alzheimer's disease dementia (AD). METHODS Longitudinal data were obtained from Arizona Study of Aging and Neurodegenerative Disease, with PDD ( n = 98), AD ( n = 47) and DLB ( n = 48) further sub‐grouped as with or without parkinsonism (DLB+ and DLB−). Within‐group Unified Parkinson's Disease Rating Scale (UPDRS) ‐II and UPDRS‐III trajectories were analyzed using non‐linear mixed effects models. RESULTS In DLB, 65.6% had parkinsonism. Baseline UPDRS‐II and III scores (off‐stage) were highest ( P < 0.001) for PDD (mean ± SD 14.3 ± 7.8 and 27.4 ± 16.3), followed by DLB+ (6.0 ± 8.8 and 17.2 ± 17.1), DLB− (1.1 ± 1.3 and 3.3 ± 5.5) and AD (3.2 ± 6.1 and 8.2 ± 13.6). Compared to PDD, the DLB+ group had faster UPDRS‐III progression over 8‐years (Cohen's‐ d range 0.98 to 2.79, P < 0.001), driven by gait ( P < 0.001) and limb bradykinesia ( P = 0.02) subscales. DISCUSSION Motor deficits progress faster in DLB+ than PDD, providing insights about expected changes in motor function. Highlights Dementia with Lewy bodies has faster motor progression than Parkinson's disease dementia Linear and non‐linear mixed modeling analysis of longitudinal data was utilized Findings have implications for clinical prognostication and trial design
Associations between neuropsychiatric symptoms, pathology, and survival in an autopsy-confirmed cohorts of Alzheimer’s disease, Alzheimer’s disease with Lewy bodies and Dementia with Lewy bodies (S39.008)
Shakir, Neha , Belden, Christine M. , Beach, Thomas G. , Tremblay, Cécilia , Zhang, Nan , Adler, Charles H. , Atri, Alireza , Serrano, Geidy E. , Choudhury, Parichita

Mayo Clinic

Neurology | April 28, 2023 | Volume: 100 | Issue: 17_supplement_2 | Pages: No page available

10.1212/wnl.0000000000203076 Get It

Low Clinical Sensitivity and Unexpectedly High Incidence for Neuropathologically Diagnosed Progressive Supranuclear Palsy (PSP) (S51.001)
Driver‐Dunckley, Erika , Dunckley, Nathaniel, Sue, Lucia I., Shill, Holly A. , Mehta, Shyamal H. , Belden, Christine M. , Beach, Thomas G. , Zhang, Nan , Serrano, Geidy E. , Tremblay, Cécilia , Atri, Alireza , Adler, Charles H.

Mayo Clinic

Neurology | April 28, 2023 | Volume: 100 | Issue: 17_supplement_2 | Pages: No page available

10.1212/wnl.0000000000202619 Get It

Cerebral white matter rarefaction has both neurodegenerative and vascular causes and may primarily be a distal axonopathy
Beach, Thomas G. , Sue, Lucia I., Scott, Sarah, Intorcia, Anthony J., Walker, Jessica E. , Arce, Richard, Glass, Michael J. , Borja, Claryssa I., Cline, Madison P. , Hemmingsen, Spencer J, Qiji, Sanaria H., Stewart, Analisa M. , Martinez, Kayleigh N, Krupp, Addison, McHattie, Rylee, Mariner, Monica, Lorenzini, Ileana , Kuramoto, Angela, Long, Kathy E., Tremblay, Cécilia , Caselli, Richard J. , Woodruff, Bryan K. , Rapscak, Steven Z., Belden, Christine M. , Goldfarb, Danielle, Driver‐Dunckley, Erika , Mehta, Shyamal H. , Shill, Holly A. , Driver-Dunckley, Erika D., Adler, C H , Choudhury, Parichita , Sabbagh, Marwan Noel , Atri, Alireza , Adler, Charles H. , Serrano, Geidy E.

Mayo Clinic

Journal of Neuropathology & Experimental Neurology | April 18, 2023 | Volume: 82 | Issue: 6 | Pages: 457-466

10.1093/jnen/nlad026 | PMID 37071794 Get It

Abstract Cerebral white matter rarefaction (CWMR) was considered by Binswanger and Alzheimer to be due to cerebral arteriolosclerosis. Renewed attention came with CT and MR brain imaging, and neuropathological studies finding a high rate of CWMR in Alzheimer disease (AD). The relative contributions of cerebrovascular disease and AD to CWMR are still uncertain. In 1181 autopsies by the Arizona Study of Aging and Neurodegenerative Disorders (AZSAND), large-format brain sections were used to grade CWMR and determine its vascular and neurodegenerative correlates. Almost all neurodegenerative diseases had more severe CWMR than the normal control group. Multivariable logistic regression models indicated that Braak neurofibrillary stage was the strongest predictor of CWMR, with additional independently significant predictors including age, cortical and diencephalic lacunar and microinfarcts, body mass index, and female sex. It appears that while AD and cerebrovascular pathology may be additive in causing CWMR, both may be solely capable of this. The typical periventricular pattern suggests that CWMR is primarily a distal axonopathy caused by dysfunction of the cell bodies of long-association corticocortical projection neurons. A consequence of these findings is that CWMR should not be viewed simply as “small vessel disease” or as a pathognomonic indicator of vascular cognitive impairment or vascular dementia.
Low clinical sensitivity and unexpectedly high incidence for neuropathologically diagnosed progressive supranuclear palsy
Driver‐Dunckley, Erika , Dunckley, Nathaniel, Sue, Lucia I., Shill, Holly A. , Mehta, Shyamal H. , Belden, Christine M. , Tremblay, Cécilia , Beach, Thomas G. , Driver-Dunckley, Erika D., Zhang, Nan , Serrano, Geidy E. , Atri, Alireza , Adler, Charles H.

Mayo Clinic

Journal of Neuropathology & Experimental Neurology | April 11, 2023 | Volume: 82 | Issue: 5 | Pages: 438-451

10.1093/jnen/nlad025 | PMID 37040756 Get It

Abstract The objective of this study was to determine the prevalence, incidence, and clinical diagnostic accuracy for neuropathologically diagnosed progressive supranuclear palsy (PSP) with data from a longitudinal clinicopathological study using Rainwater criteria to define neuropathological PSP. Of 954 autopsy cases, 101 met Rainwater criteria for the neuropathologic diagnosis of PSP. Of these, 87 were termed clinicopathological PSP as they also had either dementia or parkinsonism or both. The prevalence of clinicopathologically defined PSP subjects in the entire autopsy dataset was 9.1%, while the incidence rate was estimated at 780 per 100 000 persons per year, roughly 50-fold greater than most previous clinically determined PSP incidence estimates. A clinical diagnosis of PSP was 99.6% specific but only 9.2% sensitive based on first examination, and 99.3% specific and 20.7% sensitive based on the final clinical exam. Of the clinicopathologically defined PSP cases, 35/87 (∼40%) had no form of parkinsonism at first assessment, while this decreased to 18/83 (21.7%) at final assessment. Our study confirms a high specificity but low sensitivity for the clinical diagnosis of PSP. The low clinical sensitivity for PSP is likely primarily responsible for previous underestimates of the PSP population incidence rate.